Physician profile
Jeff Y The
NPI 1710940242
$8,200.10
in general payments reported to CMS, 2019-2025
19 companies · $1,589 in 2025
The $1,589 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $263 · 2020: $869 · 2021: $1,192 · 2022: $1,001 · 2023: $2,004 · 2024: $1,283 · 2025: $1,589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,876.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,875.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,118.79 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,374.32 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $998.67 | 2019-2025 | |
| Lilly USA, LLC | $805.37 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $740.96 | 2019-2025 | Jardiance, Tradjenta |
| Glaxosmithkline, LLC. | $598.38 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Exact Sciences Corporation | $540.26 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $335.03 | 2019-2024 | Xarelto |
| Amgen INC. | $174.39 | 2019-2024 | Krystexxa |
| Merck Sharp & Dohme LLC | $118.00 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $91.23 | 2020-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.72 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $60.13 | 2020-2024 | Eliquis |
| Abbvie INC. | $45.66 | 2021-2023 | Linzess |
| Esperion Therapeutics, INC. | $39.99 | 2020-2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $24.64 | 2023 | Jornay Pm |
| Astellas Pharma US INC | $23.78 | 2019 | |
| Shire North American Group INC | $19.91 | 2019 | |
| Currax Pharmaceuticals LLC | $15.87 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeff The listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.